Complete Response Letter on Seroquel XR for major depressive disorder

AstraZeneca announced the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information for the supplemental New Drug Application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients.

AstraZeneca is evaluating the contents of the CRL and the proposed labelling revisions. AstraZeneca will continue discussions with the FDA and will provide a response to the agency in due course.

SEROQUEL XR, a once-daily, extended release formulation of SEROQUEL (quetiapine fumarate), was approved in the U.S. in 2007 for the acute and maintenance treatment of schizophrenia in adult patients and in October 2008 for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. The CRL does not change the current recommendations for the treatment of patients taking SEROQUEL XR or SEROQUEL for approved indications in schizophrenia and bipolar disorder.

An update to AstraZeneca investors on progress will be provided when appropriate.


(Editor compiled and published Complete Response Letter on Seroquel XR for major depressive disorder at HealthNewsTrack on December 26, 2008 sourced from AstraZeneca - http://www.astrazeneca.com/)

Depression - recent articles and current news stories:

- Depression - now blood test can diagnose depression in teens
- Depression linked to eating fast food
- Migraine linked to increased risk of depression in women
- Depressed adolescents more likely to be bullied
- Working overtime work may lead to depression

Most related articles:

- Complete Response Letter on Seroquel XR for major depressive disorder
- FDA declines Fusilev NDA for colorectal cancer - 7.2
- Gardasil approval delayed for use in women ages 27 - 45 - 7.1
- Complete response letter for Cinryze for hereditary angioedema - 6.9
- Genetic link to placebo response in depression - 6.7

More related articles:

- Major depressive disorder, Depressive Disorder, Schizophrenia, Bipolar disorder, Depression, Mental health
- Risperdal Consta approved for bipolar disorder - 19.4
- Bipolar symptoms and emotional brain in youth - 18.7
- Bright light therapy eases bipolar depression - 17.1
- Study to pinpoint bipolar disorder risk factors - 17

Depression related articles:

- Pregnancy hormone predicts postpartum depression - 3.5
- Students with depression likely to drop out of college - 3.5
- Inadequate sleep may lead to depression - 3.4
- Migraine linked to increased risk of depression in women - 3.3
- Low testosterone levels linked to depression in older men - 3.3

Depression article/news source:

Read more health articles from AstraZeneca and health articles from USA.

Depression - search related terms:

Bipolar disorder, Depression, Depressive Disorder, Major depressive disorder, Mental health, Schizophrenia,
Depression books,

Searched keywords: seroquel xr (12), seroquel xr depression (5), seroquel unipolar depression (5),

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
2.86